Sumitomo Pharma America, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT00691405
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 717
- Registration Number
- NCT00685841
Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00684866
Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT00685126
A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00684827
Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00685529
Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00685022
Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00685269
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00685347
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00685425
© Copyright 2024. All Rights Reserved by MedPath